



AlexionPAC 

ANNUAL REPORT

2025

MESSAGE FROM THE CHAIR

DEL LABEL

2025 was a tremendous year for the Alexion Political Action Committee (AlexionPAC). We prioritized employee engagement and expanded the reach of Alexion's advocacy efforts. Nearly 150 colleagues collectively contributed over \$70,000 to amplify the voice of rare disease in policymaking. Our 4th Annual Charitable PAC Match Campaign yielded over \$50,000 in charitable donations to 112 charitable organizations, doubling our impact in the communities we serve. We built relationships with new Members of Congress and supported 30 bipartisan rare disease champions. I'm proud to share Alexion's fifth annual report highlighting key moments from 2025, and I look forward to building on this momentum in 2026.



Amid a challenging and fast-shifting political climate, we broke new ground with our first-ever Advocacy Day, bringing the AlexionPAC and AstraZenecaPAC Boards to Washington, D.C. to advocate on Capitol Hill. We look forward to expanding this event in the coming years.

Soon after, a major legislative priority became reality: the ORPHAN Cures Act was signed into law. This policy expands the orphan drug exclusion in Medicare's drug price negotiation program to include orphan drugs that treat multiple rare diseases, instead of just one. This change will encourage biotech companies to pursue research into new rare disease therapies and additional uses for existing ones, helping accelerate innovation and ensure rare disease patients and their families are not overlooked in favor of more common conditions. In a challenging political climate, this is a clear win for the rare disease community and for companies committed to investing in new treatments and cures.

We were proud to welcome Energy and Commerce Committee Chairman Brett Guthrie to Alexion's Boston Seaport Headquarters, with an event hosted by AlexionPAC and AstraZenecaPAC.

Advancing progress for patients living with rare diseases remains at the heart of our mission. AlexionPAC brings the rare disease perspective to Capitol Hill, ensuring our voice is heard in policy discussions that shape access to timely diagnosis, quality care, and innovative treatment. On behalf of the AlexionPAC Board of Directors, thank you to everyone who supported our advocacy over the past year. If you're not yet a member, now is the perfect time to join AlexionPAC and add your voice to this important work.

Del Lebel
Chair, AlexionPAC Board of Directors
Head of US Corporate Affairs

AlexionPAC 101:

A PAC, or a political action committee, is a key advocacy resource to facilitate employee engagement in the policymaking and political process. Alexion PAC furthers our goals as a company and advances the interests of our patients, employees, and other stakeholders. AlexionPAC focuses on what unites us as employees: working to change lives for the better –ours, people living with rare diseases, and the communities we serve. Alexion is committed to a transparent and compliant political program that advances Alexion’s strategic goals and our mission.

AlexionPAC

- *Allows you to shape the policymaking environment in support of Alexion’s mission.*
- *Gives employees direct access to the political process, and demonstrates Alexion’s commitment to policy leadership.*
- *Allows employees to pool voluntary resources to support candidates who are aligned with Alexion’s mission and values*



DIFFERENTIATE RARE DISEASE



INCREASE AWARENESS



ADVANCE POLICY PRIORITIES

2025 CAMPAIGNS

ALEXIONPAC AT AKF

AKF was a great opportunity to have some fun while educating colleagues on the critical role AlexionPAC plays in developing and supporting the next generation of rare disease policy champions in the US Congress. “Spin to Win” signed up 22 new PAC members at the AlexionPAC table. THANK YOU to AlexionPAC Board Member Scott Weintraub for speaking about the importance of the PAC in our overall advocacy efforts in his opening remarks.



CHARITABLE PAC MATCH

AlexionPAC’s 4th Annual Charitable PAC Match Campaign yielded over \$50,000 in charitable donations to 112 charitable organizations due to the commitment of colleagues like you, amplifying our impact in the communities where we live and work. During the campaign, Alexion matched (dollar-for-dollar) employee PAC contributions to their charity (or charities) of choice, allowing colleagues to make twice the impact with the same dollar.

EMPLOYEE ENGAGEMENT IN BOSTON AND NEW HAVEN

To increase awareness of the PAC, AlexionPAC hosted a happy hour for employees in the New Haven office and a Lunch and Learn for employees in the Boston office. In Boston, we were joined by Mark Williams and Cristina Antelo of Ferox Strategies who gave a preview of the 2026 midterm elections.

Exclusive Programming for AlexionPAC Members

INAUGURAL ALEXIONPAC/AZPAC ADVOCACY DAY

This year, we welcomed AlexionPAC and AstraZenecaPAC Board members to Washington, D.C. for our inaugural Advocacy Day. Our discussions focused on strengthening PAC membership and influence, while also addressing the policy challenges impacting our industry.

After an evening of networking at the Nationals vs. Cubs game, we spent a full day on Capitol Hill, advocating for policies like the ORPHAN Cures Act. PAC Board members met with Massachusetts-based Representatives Lori Trahan (D-MA) and Jake Auchincloss (D-MA), as well as Rare Disease Caucus Co-Chair Gus Bilirakis (R-FL) and staff from other Members of Congress serving on key healthcare committees, reinforcing the critical need for tailored policy solutions.



HOSTING CHAIRMAN BRETT GUTHRIE IN BOSTON

Over the summer, AlexionPAC and AZPAC joined forces to host House Energy & Commerce Chairman Brett Guthrie (R-KY) at Alexion’s Boston Seaport headquarters.

Chairman Guthrie has been a longtime champion of the rare disease community, including shepherding the passage of ORPHAN Cures and reauthorization of the rare pediatric disease priority review voucher program through the Committee this year.



2025 SPEAKER SERIES

PAC members also had the opportunity to attend exclusive conversations with Congressman Gus Bilirakis (R-FL), chair of the House Rare Disease Caucus and member of the House Energy & Commerce Committee, on policy issues impacting the rare disease community, and Congressman Don Davis (D-NC), lead Democrat sponsor of the ORPHAN Cures Act. We closed the 2025 Speaker Series by hearing from Nathan Gonzales, Editor & Publisher of Inside Elections Digest, who provided insight into the 2026 midterm elections.

More to come—join us for the 2026 AlexionPAC Speaker Series!

CANDIDATE CONTRIBUTIONS

AlexionPAC is non-partisan and decisions to support candidates are made independent of party affiliation. Contributions from AlexionPAC members in 2025 supported 30 bipartisan rare disease policy champions with a near 50/50 split between Republican and Democrat candidate contributions. To check out the full list of candidates that received contributions, visit AlexionPAC.com.

Thank You 2025 AlexionPAC Donors

DOUBLE HELIX (\$5,000)

Lee Johnson	US Commercial
Delman Lebel	Corporate Affairs
Jill Nichols	Medical Affairs
Martha Orzechowski	Medical Affairs
Tamar Thompson	Medical Affairs
Scott Weintraub	US Commercial

HELIX (\$2,500 - \$4,999)

Naeem Khan	Med
Lisa Langenderfer	Corporate Affairs
Matthew O'Donnell	Corporate Affairs
Todd Spalding	Legal

CATALYST (\$1,000 - \$2,499)

Amy Brown	US Commercial
Teresa Cutshall	US Commercial
Michael Elloian	Finance
John Eppard	US Commercial
Lucille Frierson	US Commercial
Caroline Hagedorn	Medical Affairs
Stephen Hastings	Medical Affairs
Christophe Hotermans	Medical Affairs
John Kaye	Research and Development
David King	Research and Development
Mary-Sheila Leese	US Commercial
Cesar Melgoza	US Commercial
Kelly Morse	Research and Development
Gretchen Prins	US Commercial
Brian Rosen	Corporate Affairs
Monique Taylor	US Commercial

INNOVATOR (\$500 - \$999)

Ann Adams	Medical Affairs
Amna Ahmed	Technology Experience
Ravinder Bajwa	Technology Experience
Jennifer Bradley	Research and Development
Kelley Brant	US Commercial
John Bullard	US Commercial
Douglas Calandra	US Commercial

INNOVATOR (\$500 - \$999)

Julia Catini	Research and Development
Rhonda Duggan	US Commercial
Lisa Feng	Corporate Affairs
Shaun Fitzmorris	US Commercial
Christy Foote	US Commercial
Stephen LaRosa	Finance
Rochelle Liverman	Research and Development
Nikki Marsh	US Commercial
Kelly McNeil-Posey	Medical Affairs
Brian Meltzer	Research and Development
Sonali Mody	Research and Development
Audrey Rattan	US Commercial
Caleb Sellers	US Commercial
John Waite	US Commercial
Yan Wang	Medical Affairs
Deborah Ware	US Commercial

Thank You 2025 AlexionPAC Donors

PARTNER (\$240 - \$499)

Lisa Adams	US Commercial
Sharon Bailey	US Commercial
Michelle Belliveau	Medical Affairs
Jacyntha Billingsley	US Commercial
Stephen Blumm	US Commercial
Nicole BoBo	US Commercial
Ruba Bou-Chahine	Research and Development
Bonnie Brogle	US Commercial
Ryan Burcham	US Commercial
Jordan Cabral	Research and Development
Chanse Carter	US Commercial
Lisa Cheney	US Commercial
Lance Conley	US Commercial
Corinne Copeland	US Commercial
Shari Cretella	US Commercial
Joan Curto	US Commercial
Teresa Cutshall	US Commercial
Colleen Dabbene	US Commercial
Drapadi Daley	US Commercial
Jennifer Dardis	US Commercial
Christian Darland	US Commercial
Shannon Donovan	US Commercial
Jerri Durnell	US Commercial
Michael Enright	US Commercial
Stacie Fauchaux	US Commercial
Christine Freitas	US Commercial
Antonio Garcia	US Commercial
Ralph Geer	US Commercial
Herman Genderson	US Commercial
David Grussing	US Commercial
Karen Haire	Research and Development
Margaret Hall	US Commercial
Sarah Brett Hansen	US Commercial
Stacey Harris	US Commercial
Donald Healy	US Commercial
David Hoover	US Commercial
Johnny Howard	US Commercial
Christine Hutchins-Chavez	US Commercial
Davis Jeffers	US Commercial
Nanette Justiniano	US Commercial
Salma Kiani	Research and Development
Wendy King	US Commercial
Deena Kreutzer	US Commercial
Najwa Lamnii	Research and Development
Melissa Lasaro	Research and Development
Peter Lefavour	US Commercial
Christa Lizzi	US Commercial
Craig Mansfield	Human Experience

PARTNER CONT. (\$240 - \$499)

Brittany McCarron	US Commercial
MacKenzie McConville	US Commercial
Susan Mercer	Medical Affairs
Edmund Moore III	US Commercial
Elizabeth Morgan	Research and Development
Dina Morill	Technology Experience
Dean Oachs	US Commercial
Vicki Oberkrom	US Commercial
Amisha Patel	Research and Development
Amanda Phillips	Medical Affairs
Jason Phillips	US Commercial
Kellie Pierce	US Commercial
Cynthia Rice	US Commercial
Luis Rodriguez	Corporate Affairs
Ann Sadowsky	US Commercial
Joy Saiontz	US Commercial
Lauren Savage	US Commercial
Samuel Sealey	US Commercial
Brian Shank	Corporate Affairs
Trenna Shaw	Research and Development
Natasa Sokolovich	US Commercial
Terri Stegman	US Commercial
Elizabeth Tawil	US Commercial
Sandra Tefft	US Commercial
Tri Tran	US Commercial
Vijay Vaidya	Technology Experience
Rebekah Whitfield	US Commercial
Bao Zhang	Research and Development

MEMBERS (LESS THAN \$240)

Terrya Addae	Research and Development
Leonie Bock	Research and Development
Crystal Cope	US Commercial
Michelle Cosgrove	US Commercial
Karen Franks	US Commercial
Debra Gonzalez	US Commercial
Maria Hansen	Finance
Michelle Kielbasa	US Commercial
Dana Kornfeld	US Commercial
John Moleiro	Technology Experience
Jennifer Pocoski	US Commercial
Adam Pool	US Commercial
Karen Rankin	US Commercial
Avner Sandhu	Research and Development
Brian Souto	US Commercial
Mukesh Sharma	US Commercial
John Stoner	Medical Affairs
David Turpen	US Commercial
Matthew Wuhrer	Research and Development

Thank you for your support and dedication, and we hope you'll continue to stand with us in 2026 as we keep fighting for the rare disease community.

Make a difference today at AlexionPAC.com.



Alexion Pharmaceuticals Inc. PAC is the federal political action committee of Alexion Pharmaceuticals Inc. Individual contributions to Alexion Pharmaceuticals Inc. PAC are used to support candidates who are running for federal office.

Contributions to Alexion Pharmaceuticals Inc. PAC are not tax deductible. Contributions are strictly voluntary and will be used for political purposes. You have the right to refuse to contribute without any reprisal. Making a contribution to Alexion Pharmaceuticals Inc. PAC does not increase your chances of winning.